Literature DB >> 17356175

Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: helical CT and MR imaging findings with clinical-pathologic comparison.

Riccardo Iannaccone1, Francesca Piacentini, Takamichi Murakami, Valérie Paradis, Jacques Belghiti, Masatoshi Hori, Tonsok Kim, François Durand, Kenichi Wakasa, Morito Monden, Hironobu Nakamura, Roberto Passariello, Valérie Vilgrain.   

Abstract

PURPOSE: To retrospectively evaluate the clinical, pathologic, and helical computed tomographic (CT) and magnetic resonance (MR) imaging findings of hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease (NAFLD).
MATERIALS AND METHODS: Institutional review board approval was obtained for this study; the need for patient informed consent was waived. Clinical, pathologic, and imaging findings were retrospectively evaluated in 22 men (mean age, 64.5 years) with HCC and NAFLD. Helical CT and MR images were reviewed for morphologic features such as tumor size, margins, necrosis, and degree of enhancement.
RESULTS: Obesity, diabetes, and hypertension were common findings and were observed in 12 (55%), 14 (64%), and 13 (59%) of the 22 patients, respectively. The serum alpha-fetoprotein level was elevated in eight patients (36%). All patients had pathologic evidence of NAFLD. HCC was well-differentiated in seven patients, moderately differentiated in 11, and poorly differentiated in four. Large tumors (mean diameter, 8.4 cm) were depicted at CT and/or MR imaging in all patients. Twenty-one patients had a solitary or dominant mass. At imaging, tumor margins were well defined in 17 patients, with a smooth surface in 17, and there was evidence of a tumor capsule in 15. Necrosis was depicted in 16 patients. There was no evidence of calcifications, central scar, fat, or abdominal lymphadenopathy. CT was performed in 20 patients. HCC was hypoattenuating on unenhanced CT scans in 14 patients, heterogeneously hyperattenuating in the arterial phase in 20, and hypoattenuating in the portal phase in 14. MR imaging was performed in 16 patients. HCC was hyperintense compared with liver parenchyma at T2-weighted MR imaging in all 16 patients, hypointense at T1-weighted imaging in 14, heterogeneously hyperintense at arterial phase T1-weighted imaging in 16, and hypointense at portal phase T1-weighted imaging in 14.
CONCLUSION: HCC in patients with NAFLD is more likely to manifest as a large solitary or dominant mass characterized by smooth and possibly encapsulated margins, necrosis, and hypervascularity.

Entities:  

Mesh:

Year:  2007        PMID: 17356175     DOI: 10.1148/radiol.2432051244

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  22 in total

1.  Obesity and microvascular invasion in hepatocellular carcinoma.

Authors:  Abby B Siegel; Shuang Wang; Judith S Jacobson; Dawn L Hershman; Emerson A Lim; Jeanette Yu; Lauren Ferrante; Kalpana M Devaraj; Helen Remotti; Shannon Scrudato; Karim Halazun; Jean Emond; Lorna Dove; Robert S Brown; Alfred I Neugut
Journal:  Cancer Invest       Date:  2010-12       Impact factor: 2.176

2.  Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine.

Authors:  Elango Kathirvel; Kengathevy Morgan; Ganesh Nandgiri; Brian C Sandoval; Marie A Caudill; Teodoro Bottiglieri; Samuel W French; Timothy R Morgan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-08-19       Impact factor: 4.052

3.  Mapping of liver fat with triple-echo gradient echo imaging: validation against 3.0-T proton MR spectroscopy.

Authors:  Boris Guiu; Romaric Loffroy; Jean-Michel Petit; Serge Aho; Douraied Ben Salem; David Masson; Patrick Hillon; Jean-Pierre Cercueil; Denis Krause
Journal:  Eur Radiol       Date:  2009-02-27       Impact factor: 5.315

4.  Sequential arterial and portal vein embolization in patients with cirrhosis and hepatocellular carcinoma: the hospital beaujon experience.

Authors:  Valérie Vilgrain; Annie Sibert; Magaly Zappa; Jacques Belghiti
Journal:  Semin Intervent Radiol       Date:  2008-06       Impact factor: 1.513

5.  Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical, radiological and pathological findings.

Authors:  Michele Di Martino; Luca Saba; Sandro Bosco; Massimo Rossi; Kirchin A Miles; Rossella Di Miscio; Concetta Valentina Lombardo; Elisabetta Tamponi; Mario Piga; Carlo Catalano
Journal:  Eur Radiol       Date:  2014-04-26       Impact factor: 5.315

6.  Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.

Authors:  Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh
Journal:  Br J Radiol       Date:  2018-08-29       Impact factor: 3.039

7.  LI-RADS v2017 categorisation of HCC using CT: Does moderate to severe fatty liver affect accuracy?

Authors:  Seung Soo Kim; Jeong Ah Hwang; Hyeong Cheol Shin; Seo-Youn Choi; Tae Wook Kang; Sung Shick Jou; Woong Hee Lee; Suyeon Park; Nam Hun Heo
Journal:  Eur Radiol       Date:  2018-08-02       Impact factor: 5.315

Review 8.  Imaging of liver cancer.

Authors:  Ben Ariff; Claire R Lloyd; Sameer Khan; Mohamed Shariff; Andrew V Thillainayagam; Devinder S Bansi; Shahid A Khan; Simon D Taylor-Robinson; Adrian K P Lim
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

9.  Epithelioid angiomyolipoma of the liver: cross-sectional imaging findings of 10 immunohistochemically-verified cases.

Authors:  Peng-Ju Xu; Yan Shan; Fu-Hua Yan; Yuan Ji; Ying Ding; Mei-Lin Zhou
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

Review 10.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.